Saniona Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Saniona hat ein Gesamteigenkapital von SEK6.9M und eine Gesamtverschuldung von SEK39.9M, was einen Verschuldungsgrad von 574.8% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK92.5M bzw. SEK85.5M.

Wichtige Informationen

574.8%

Verhältnis von Schulden zu Eigenkapital

SEK 39.86m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 54.39m
Eigenkapital	SEK 6.93m
Gesamtverbindlichkeiten	SEK 85.53m
Gesamtvermögen	SEK 92.46m

Jüngste Berichte zur Finanzlage

Recent updates

Is Saniona (STO:SANION) Using Debt Sensibly?

Nov 06

Is Saniona (STO:SANION) Weighed On By Its Debt Load?

Jul 30

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Nov 29

Is Saniona (STO:SANION) Using Too Much Debt?

Aug 16

Is Saniona (STO:SANION) Using Too Much Debt?

Mar 17

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Feb 10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SANIONDie kurzfristigen Aktiva des Unternehmens (SEK74.2M) übersteigen seine kurzfristigen Passiva (SEK17.5M).

Langfristige Verbindlichkeiten: SANIONDie kurzfristigen Vermögenswerte des Unternehmens (SEK74.2M) übersteigen seine langfristigen Verbindlichkeiten (SEK68.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SANION über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: SANIONDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 15.2% auf 574.8% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: SANION hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: SANION hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 13% pro Jahr abnimmt

Saniona Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Saniona (STO:SANION) Using Debt Sensibly?

Is Saniona (STO:SANION) Weighed On By Its Debt Load?

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Is Saniona (STO:SANION) Using Too Much Debt?

Is Saniona (STO:SANION) Using Too Much Debt?

Is Saniona (STO:SANION) Using Too Much Debt?

Recent updates

Is Saniona (STO:SANION) Using Debt Sensibly?

Saniona Initiates SAN711 Biomarker Study

Saniona Receives Regulatory Approval for San711 Biomarker Study

New major risk - Financial position

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

Is Saniona (STO:SANION) Weighed On By Its Debt Load?

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

New major risk - Shareholder dilution

Price target decreased by 37% to kr6.00

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

Is Saniona (STO:SANION) Using Too Much Debt?

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

President & CEO recently bought kr100k worth of stock

Independent Chairman of the Board recently bought kr229k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Is Saniona (STO:SANION) Using Too Much Debt?

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: kr18.70

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: kr20.10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

New 90-day low: kr20.70

Saniona Announces Management Appointments

Co-Founder recently bought kr108k worth of stock

Co-Founder recently bought kr115k worth of stock

New 90-day low: kr22.55

Is Saniona (STO:SANION) Using Too Much Debt?

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: kr24.70

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)